Nasdaq:KNSA
Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals is a biopharma innovator turning profitable in 2025 with $677.6M revenue driven by oncology and autoimmune biologics.
Key Metrics
Investment Thesis
Bull Case
Investors should consider buying Kiniksa due to its successful transition back to profitability with $59.0M net income in 2025 after years of losses; the robust cash position of $165.6M and low capital burn rate suggest a sustainable path for future R&D investments; continued revenue growth of over 50% year-over-year validates the commercial success of its differentiated biologics portfolio.
Bear Case
Potential buyers should avoid the stock given the massive cash outflow from investing activities of -$189.0M which may indicate heavy asset restructuring or impairment charges not fully captured in net income; the large retained earnings deficit of -$462.1M signals historical burn that investors must monitor for recurring cash flow sustainability; high general and administrative expenses of $196.3M relative to revenue could compress margins if sales growth decelerates.
About Kiniksa Pharmaceuticals International, plc
Kiniksa Pharmaceuticals International focuses on discovering and developing novel therapeutics for oncology, autoimmune diseases, and rare disorders. The company leverages its proprietary technology platform to generate biologics, serving markets across the United States and globally with a portfolio targeting high-need areas like cancer immunotherapy. With 2025 revenue reaching $677.6M and a return to profitability with $59.0M net income, the firm demonstrates strong operational scaling.
Analysis
Management Discussion
The company achieved a remarkable turnaround in 2025, posting $59.0M net income and growing revenue to $677.6M from $423.2M the prior year. Strong operating cash flow of $138.0M indicates improved collection efficiency with accounts receivable at $15.6M, while capital expenditures remained low at $1.6M, suggesting a mature and efficient manufacturing operation.
Industry Overview
The biopharmaceutical industry is currently focused on developing novel mechanisms of action for oncology and autoimmune diseases, where Kiniksa competes with major players like Genentech and Regeneron. Regulatory hurdles remain high, but the shift toward personalized biologics creates opportunities for specialized firms like Kiniksa to capture market share. The sector demands significant R&D investment, yet recent profitability suggests a maturing environment for mid-cap innovators.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $220.2M | $270.3M | $423.2M | $677.6M |
| Cost of Revenue | $0 | $0 | $60.9M | $77.7M |
| Gross Profit | $220.2M | $270.3M | $362.3M | $599.9M |
| Operating Expenses | $210.4M | $295.5M | $407.9M | $522.7M |
| Operating Income | $9.8M | $-25.2M | $-45.6M | $77.2M |
| R&D | $65.5M | $76.1M | $111.6M | $96.9M |
| G&A | $98.0M | $129.4M | $168.0M | $196.3M |
| Stock-Based Comp | $25.1M | $27.1M | $30.7M | $37.0M |
| D&A | $2.4M | $2.3M | $1.7M | $1.6M |
| Depreciation | $1.2M | $1.1M | $448.0K | $196.0K |
| Other OpEx | $47.0M | $89.9M | $128.3M | $229.5M |
| Non-Operating Income | $1.3M | $8.5M | $9.5M | $11.6M |
| Interest Income | — | — | $9.0M | $11.6M |
| Pre-Tax Income | $11.0M | $-16.7M | $-36.2M | $88.9M |
| Income Tax | $-172.3M | $-30.7M | $7.0M | $29.9M |
| Continuing Ops | $183.4M | $14.1M | $-43.2M | $59.0M |
| Discontinued Ops | $0 | $0 | $0 | $0 |
| Net Income | $183.4M | $14.1M | $-43.2M | $59.0M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $183.4M | $14.1M | $-43.2M | $59.0M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $243.1M | $276.3M | $331.8M | $527.2M |
| Cash & Equivalents | $122.7M | $108.0M | $183.6M | $165.6M |
| Marketable Securities | $67.9M | $98.4M | $60.0M | $248.5M |
| Accounts Receivable | $12.7M | $21.3M | $41.7M | $15.6M |
| Inventory | $21.6M | $31.1M | $26.4M | $54.9M |
| Prepaid Expenses | $10.5M | $17.5M | $20.1M | $42.6M |
| Other Current Assets | $7.7M | $0 | $0 | $0 |
| Long-Term Assets | $216.6M | $250.0M | $248.8M | $236.5M |
| PP&E (Net) | $1.7M | $734.0K | $662.0K | $1.9M |
| Operating Leases | $5.4M | $11.9M | $10.4M | $9.8M |
| Other LT Assets | $209.6M | $237.4M | $237.7M | $224.7M |
| Total Assets | $459.7M | $526.3M | $580.6M | $763.6M |
| Current Liabilities | $47.1M | $63.7M | $100.6M | $139.2M |
| Accounts Payable | $7.9M | $8.2M | $2.0M | $2.0M |
| Current Leases | $3.3M | $2.3M | $2.0M | $3.0M |
| Deferred Revenue | — | $307.0K | — | — |
| Other Current Liab | $5.8M | $8.2M | $64.2M | $92.1M |
| Long-Term Liabilities | $16.5M | $23.8M | $41.5M | $56.8M |
| LT Operating Leases | $2.6M | $10.0M | $7.9M | $6.5M |
| Other LT Liab | $1.8M | $1.9M | $1.8M | $18.5M |
| Total Liabilities | $63.5M | $87.5M | $142.1M | $196.0M |
| Shareholders' Equity | $396.1M | $438.8M | $438.4M | $567.6M |
| Paid-In Capital | $888.1M | $916.8M | $959.7M | $1.03B |
| Retained Earnings | $-492.0M | $-477.9M | $-521.1M | $-462.1M |
| AOCI | $44.0K | $6.0K | $-163.0K | $-25.0K |
| Total L&E | $459.7M | $526.3M | $580.6M | $763.6M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $183.4M | $14.1M | $-43.2M | $59.0M |
| Non-Cash Adjustments | $-228.9M | $-31.3M | $-16.2M | $-1.4M |
| Working Capital Changes | $51.4M | $30.5M | $85.1M | $80.4M |
| Cash from Operations | $5.8M | $13.3M | $25.7M | $138.0M |
| Capital Expenditures | $105.0K | $130.0K | $277.0K | $1.6M |
| Cash from Investing | $-8.1M | $-29.6M | $37.7M | $-189.0M |
| Cash from Financing | $2.5M | $1.5M | $12.3M | $33.0M |
| FX Effect | $0 | $0 | $0 | $0 |
| Net Change in Cash | $245.0K | $-14.8M | $75.6M | $-18.0M |
| Beginning Cash | $122.5M | $122.7M | $108.0M | $183.6M |
| Ending Cash | $122.7M | $108.0M | $183.6M | $165.6M |
Frequently Asked Questions
How does Kiniksa Pharmaceuticals International, plc make money?
The company's revenue streams are primarily derived from its proprietary biologics platform, generating income through product sales or licensing agreements for cancer immunotherapies, treatments for autoimmune conditions like psoriasis, and therapies for rare genetic diseases.
What are the main risks for KNSA?
Significant regulatory uncertainty exists as new biologic products face rigorous FDA approval processes that can delay commercialization; the company faces intense patent expiration risks which could erode revenue from its blockbuster oncology drugs; high operating expenses of $522.7M create pressure on margins if sales growth slows; reliance on a limited number of key product candidates creates concentration risk in the event of clinical trial failures.
What is KNSA's competitive advantage?
Kiniksa maintains a moat through its unique dual-specificity antibody technology that enhances immune cell efficacy; the firm benefits from high switching costs as patients rely on specialized biologics not easily replicated by competitors; substantial cash reserves of $165.6M provide flexibility for R&D expansion without immediate dilution.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.